Adaptive Biotechnologies (ADPT) FCF Margin (2018 - 2026)

Adaptive Biotechnologies has disclosed FCF Margin across 9 years of filings, most recently posting 10.6% for Q2 2026.

• In Q2 2026, FCF Margin rose 1162.0% year-over-year to 10.6%; the TTM figure through Jun 2026 stood at 7.8% (up 3255.0% YoY), while the FY2025 annual figure was 17.67%, up 3758.0% from the prior year.
• FCF Margin came in at 10.6% for Q2 2026 at Adaptive Biotechnologies, up from 14.58% in the prior quarter.
• In the past five years, FCF Margin ranged from a high of 1.98% in Q4 2025 to a low of 174.86% in Q1 2022.
• Average FCF Margin over 5 years is 66.75%, with a median of 57.85% recorded in 2022.
• Year-over-year, FCF Margin surged 10729 bps in 2022 and slumped 3042 bps in 2023.
• Over 5 years, FCF Margin stood at 58.99% in 2022, then retreated by 5 bps to 61.66% in 2023, then surged by 57 bps to 26.49% in 2024, then soared by 107 bps to 1.98% in 2025, then sank by 635 bps to 10.6% in 2026.
• Per Business Quant data, the three most recent FCF Margin figures were 10.6% in Q2 2026, 14.58% in Q1 2026, and 1.98% in Q4 2025.